

10648-0001-0 PCT



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF

DAVID FAIRLIE ET AL

SERIAL NO: 09/446,109

FILED: APRIL 12, 2000

: EXAMINER: MOHAMED

: GROUP ART UNIT: 1653

FOR: CYCLIC AGONISTS AND
ANTAGONISTS OF C5A
RECEPTORS AND G PROTEIN-
COUPLED RECEPTORS

PRELIMINARY AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Responsive to the Office Communication dated January 3, 2001, Applicants submit herewith a Sequence Listing and a corresponding computer-readable Sequence Listing. Prior to examination on the merits, please amend the above-identified application as follows.

IN THE SPECIFICATION

Please amend the specification as shown in the marked-up copy to read as follows:

Page 29, lines 3-20, please replace the paragraph as follows:

--We have focussed on the C-terminal residues of C5a, in order to explore structure-activity relationships in the search for peptide sequences with potent agonist activity. Many of these peptides are full agonists relative to C5a, but have markedly lower potency (Sanderson et al, 1994, 1995; Finch et al, 1997). Our initial structure-activity investigations have been particularly informative. Mutating the decapeptide C-

RECEIVED
MAY 07 2001
TECH CENTER 1600/2900
*PRE AMENDT/B
AT P 5-10
5-10*